Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.47 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.47 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326703 | 1.00 | EED (0.47) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL635787 | 1.00 | EED (0.47) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL634514 | 1.00 | EED (0.47) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL3057329 | 1.00 | EED (0.47) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL14481599 | 0.93 | CNR1 (0.44) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL14972447 | 0.93 | CNR1 (0.44) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL4245243 | 0.93 | EED (0.54) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL13326709 | 0.85 | CNR1 (0.46) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL13677624 | 0.84 | GPR119 (0.42) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL635710 | 0.81 | KDM4C (0.37) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419405-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | Theravance, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120910-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267743-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267743-A1 | 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS | HTR3C, SLC6A2, ADRB3 | EED 1673/4885RBBP4 569/4885SUZ12 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.